Biomedical subjects

I V Driazhenkova

Publications and source records attributed to I V Driazhenkova.

4 recordsLinked to original sources

PubMed2005

[Pulmonary pathology in patients with systemic lupus erythematosus].

AIM: To characterize pulmonary lesion in systemic lupus erythematosus (SLE) on the basis of clinical device and biochemical examination regarding features of the disease onset and development. MATERIAL AND METHODS: The study included 60 SLE patients. Mean age 41.1 +/- 1.32 years. Mean SLE duration 12.42 +/- 1.06 years. Activity according to the SLEDAI and ECLAM indices--16.23 +/- 0.93 and 3.09 +/- 0.18 scores, respectively. The comparison groups: 30 patients with bronchial asthma (BA), 15--with chronic bronchitis (CB), 15--with chronic obstructive bronchitis (COB), 30 healthy donors. The following parameters were studied: spirometric, bodyplethismographic evidence, diffuse ability of the lungs (DAL), plasm concentrations of adrenaline, noradrenaline, dopamine, serotonine, histamine, hemodynamics, anxiety, depression, social adaptation (quality of life) and vegetative dysfunctions. Statistics were obtained with BIOSTATISTIKA program. RESULTS: DAL depends on duration of SLE, severity of lung hypertension (LH), severity of anemia. LH in SLE deteriorated vegetative disorders and social adaptation. Lowering of plasm dopamine concentration was accompanied with LH, formation of vegetative dysfunction and worse social adaptation. CONCLUSION: Affection of the lungs in SLE patients runs without evident clinical symptoms. Initial signs of lung affection manifest with low DAL, LH, moderate restrictive, obstructive and mixed disorders of external respiration function.

Adult↗

PubMed2005

[The diastolic dysfunction of the left ventricle in patients with systemic lupus erythematosus and system scleroderma].

The subjects of the study were 22 patients with systemic lupus erythematosus (SLE) and 18 patients with system scleroderma (SS). The mean age of the subjects was 36.3 +/- 2.4 years, the onset of the disease had taken place 5 to 10 years ago. The control group consisted of 20 practically healthy individuals with no complaints, clinical signs or instrumental data suggesting cardiovascular pathology. In order to evaluate the character of left ventricular (LV) diastolic filling, all the patients underwent transthoracal Doppler analysis with measurement of transmitral flow in four-chamber heart position using apical approach with the control volume at the level of the ends of mitral valvular cusps (computed sonography system ACUSON 128 XP/10). The study found no significant difference between SLE and SS patients in such parameters as LV myocardial mass and LV mass index. All the patients with rheumatic diseases, with or without arterial hypertension (AH), had diastolic dysfunction, which was manifested by increase of atrial systolic contribution into LV filling, prolongation of blood flow slowdown time in the stage of its early filling, and prolongation of LV isometric relaxation time; heart diastolic disorder was accompanied by significant increase of end diastolic pressure in LV cavity. It should be noted that the most prominent changes were found in rheumatic patients with AH, which must be caused by the hypertrophy and remodeling of the myocardium. Myocardial hypertrophy was associated with substantial changes in the ventricular septum, which consisted in its hypokinesia, associated with impairment of myocardial contractility (ejection fraction of 48.3 +/- 3.5%).

Adult↗

PubMed2004

[Systemic vasculitis as an interdisciplinary problem].

Systemic vasculitis (SV) is characterized by generalized vascular bed lesion involving vessels of different sizes into a pathological process. The paper presents the results of a follow-up of 500 patients with different forms of SV, by making studies of immunity and the hemostatic system, angioscanning, Doppler ultrasound study of vessels, electrophysiological studies (rheoencephalography, encephalography), computed and magnetic resonance imaging of the brain, and visceral ultrasonography. A variety of clinical symptoms and involvement of different organs determine the interest of physicians of different specialties in the diagnosis and treatment of SV. The involvement of the nervous system in the process occurs in all forms of vasculitis, by afflicting the central, peripheral, and autonomic nervous systems with the development of regulatory and functional disorders. Lesions of the visual organ are typical of nonspecific aortoarteritis (Takayasu's disease), Wegener's granulomatosis, giant-cell arteritis. Recurrent uveitis is characterized in Behcet's syndrome. Cutaneous manifestations are included into the classification criteria of nodal polyartheritis, hemorrhagic vasculitis, and Kawasaki's disease. ENT and oral involvement are observed in Wegener's granulomatosis.

Arterial Occlusive Diseases↗

PubMed1998

[Neurovascular syndrome in some rheumatic diseases].

AIM: Assessment of neuromotor system and suprasegmentary vegetative structures in patients with systemic vasculitis (SV), systemic lupus erythematosus (SLE), scleroderma systematica (SS) for determination of the vegetative profile and pathogenetic links underlying vegetative disorders. MATERIALS AND METHODS: The examination of 125 rheumatic patients included clinical, laboratory, instrumental, neurological, neuropsychic, electroneuromyographic, vegetologic, pathomorphologic and biochemical investigations. RESULTS: Rheumatic patients presented affections of the peripheral and central venous systems, vegetative dysfunction, disturbed higher nervous activity manifesting as polyneuropathy, mononeuropathy, pyramid syndrome, dystonia, hypothalamic syndrome, reduced adaptive ability, low tonicity of the sympathetic nervous system, terminal branches of the motor axons, etc. CONCLUSION: Therapy of nervous disorders in rheumatic patients comprises treatment of cerebral circulation (vascular, nootropic drugs, cerebrolysin), asthenic, neurotic and vegetative disorders (sedative and vegetotropic drugs, etimisol, adaptogens), abnormalities of peripheral nervous system (amiridin, anticholinesterase preparations, vitamins B and others). Follow-up and correction of the on-going therapy contribute to a decrease in the number of invalidating and lethal neurological complications.

Diagnosis, Differential↗